Study Summaries

Docetaxel-carboplatin is similar to paclitaxel-carboplatin in terms of progression-free survival and overall response but has significantly less neurotoxicity. It represents an alternative first-line chemotherapy regimen for patients with newly diagnosed ovarian cancer.

Weekly paclitaxel did not significantly extend progression-free survival (PFS) compared to every-3-week paclitaxel overall.

IP administration of cisplatin and paclitaxel significantly improves both progression-free and overall survival in patients with optimally debulked stage III ovarian cancer compared to standard IV therapy, despite increased toxicities.

The combination of carboplatin and paclitaxel is not inferior to cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer. Carboplatin plus paclitaxel results in less toxicity and is easier to administer.

Primary chemotherapy followed by delayed surgery is non-inferior to primary surgery followed by chemotherapy in women with advanced ovarian cancer, with reduced surgical morbidity and mortality.

Neoadjuvant chemotherapy followed by interval debulking surgery is not inferior to primary debulking surgery followed by chemotherapy in patients with bulky stage IIIC or IV ovarian carcinoma. Complete resection of all macroscopic disease remains the objective in cytoreductive surgery.

Completeness of surgical staging is a significant prognostic factor, with better outcomes observed in optimally staged patients. Adjuvant chemotherapy benefits appear restricted to nonoptimally staged patients.